BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bioreason Inc. Launches ClassPharmer(TM) Suite Lite For Lead Optimization And Predictive Tox


10/19/2005 5:12:19 PM

SANTA FE, N.M., Nov. 29 /PRNewswire/ -- Bioreason, Inc., announced today the release of ClassPharmer(TM) Suite Lite, a new edition of the company's software system to increase success in the hits-to-leads-to-clinic process within drug discovery. ClassPharmer(TM) Suite Lite is available from Bioreason's website for a free 30 day evaluation.

ClassPharmer(TM) Suite Lite includes all classification, modeling and structure-property-relationship extraction functionalities of the Desktop, Server and Batch editions and is capable of analyzing up to 2,000 compounds. The cost is 3,000 USD/EUR for a one-year license.

ClassPharmer(TM) Suite Lite makes Bioreason's patented technology affordable to drug discovery scientists involved in hit-to-lead, lead optimization and chemical toxicology analysis. Proven benefits include:

Increasing "true" hit recovery -- One customer using structure-guided consensus-scoring methods reported that ClassPharmer(TM) Suite increased the recovery of "true" hits by 200-300% in a virtual screen of 1,000 molecules.

Identifying novel leads and toxicophores -- One customer reported that ClassPharmer(TM) Suite Lite found a new structural motif they had not identified previously with any other in-house tools.

Reducing optimization time -- One customer reported that ClassPharmer(TM) Suite Lite had cut by 30% the time required for hit-to-lead and lead optimization.

With the new release, all 4 Editions of ClassPharmer(TM) Suite (Lite, Desktop, Server and Batch) offer new features that greatly improve the user's control over clustering and class modeling. Dr. Patricia Bacha, Product Manager for ClassPharmer(TM) Suite at Bioreason, explained, "There was a demand for our patented clustering algorithm to be more flexible. We added new clustering options such as using fuzzy atoms, created a post-processing step that organizes the classes into families, and allowed users to further refine the classification manually by merging classes."

Dr. Andrew DePristo, President and CEO of Bioreason, concluded, "The new version demonstrates our commitment to develop software to meet our customers' changing needs. Now, every Medicinal Chemist and Toxicologist can afford to have ClassPharmer(TM) Suite on the desktop!"

Bioreason, Inc., is headquartered in Santa Fe, NM with sales and support offices in Strasbourg (France) and is represented by CTC Laboratory Systems in Japan. Bioreason provides knowledge-based software, services, and collaborations that help increase the success of the hits-to-leads-to-clinic process in drug discovery. For information on the company, see http://www.bioreason.com/.

Bioreason, Inc.

CONTACT: Andrew DePristo, President and CEO of Bioreason, Inc.,+1-505-995-8188, depristo@bioreason.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES